Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Frequently asked questions
What sector does Biovica International AB (publ) (BIOVIC-B) operate in?
Biovica International AB (publ) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Biovica International AB (publ) (BIOVIC-B) current stock price?
As of the latest data, Biovica International AB (publ) stock price is SEK 0.53, with a previous close of SEK 0.52. Biovica International AB (publ) gained SEK 0.01 in the last trading session, representing a 1.15% increase.
What is Biovica International AB (publ) (BIOVIC-B) current market capitalization?
Biovica International AB (publ) market cap is approximately 147.07 million.
What is Biovica International AB (publ) (BIOVIC-B) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.30, and the forward EPS is -SEK 0.20.
What is Biovica International AB (publ) (BIOVIC-B) EBITDA?
Biovica International AB (publ) EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -16.10 million.
Does Biovica International AB (publ) (BIOVIC-B) pay dividends?
No. Biovica International AB (publ) does not pay a dividend.
What is Biovica International AB (publ) (BIOVIC-B) beta (volatility) score?
Biovica International AB (publ) has a beta of 1.155, meaning its volatility is roughly in line with the market.
